SCHEMBL4774750

SCHEMBL4774750

CC(C)OC(=O)N1CCCC(=O)c2cscc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.34
BCHE P06276 1/20 0.34
MAPT P10636 3/20 0.34
ALDH1A1 P00352 3/20 0.34
HPGD P15428 3/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
TSHR P16473 2/20 0.33
LMNA P02545 2/20 0.33
NOTUM Q6P988 2/20 0.32
P2RX4 Q99571 1/20 0.31
SRD5A1 P18405 1/20 0.31
SCN9A Q15858 1/20 0.31
SCN10A Q9Y5Y9 1/20 0.31
NPSR1 Q6W5P4 1/20 0.30
MEN1 O00255 2/20 0.30
KMT2A Q03164 2/20 0.30
CYP1A2 P05177 1/20 0.30
CYP2D6 P10635 1/20 0.30
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3535539 0.80 NOTUM (0.48) BCHEMAPTALDH1A1HPGDRAB9A
SCHEMBL11888090 0.78 KDM4E (0.39) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL3532281 0.78 SLC6A15 (0.41) KDM4EALDH1A1HPGDNOTUMMEN1
SCHEMBL2475676 0.77 KDM4E (0.41) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL2475561 0.75 ABHD6 (0.46) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL3530779 0.75 ABHD6 (0.44) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL2472502 0.74 P2RX4 (0.34) KDM4EBCHEMAPTALDH1A1HPGD
SCHEMBL4770254 0.74 BCHE (0.32) BCHEMAPT
SCHEMBL3527205 0.74 KDM4E (0.33) KDM4EMAPTALDH1A1HPGDNPC1
SCHEMBL4534739 0.73 LMNA (0.48) KDM4EMAPTALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732933-B1 COMPOUNDS FOR TREATING DYSLIPIDEMIA LILLY CO ELI (US) 2008-07-23 EP disclosed
EP-1732933-B1 COMPOUNDS FOR TREATING DYSLIPIDEMIA LILLY CO ELI (US) 2008-07-23 EP disclosed
US-20070208003-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY 2007-09-06 US disclosed
US-20070208003-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY 2007-09-06 US disclosed
US-20070208003-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY 2007-09-06 US disclosed
EP-1732933-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2006-12-20 EP disclosed
WO-2005097805-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA ELI LILLY AND COMPANY (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208003-A1 COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA PCSK9, LIPC, APOB KDM4E 1101/4885BCHE 608/4885MAPT 4615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.